인쇄하기
취소

Samsung Bioepis agrees on ‘SB5’ patent conflict with AbbVie

Published: 2018-04-10 10:29:15
Updated: 2018-04-10 10:29:15

Samsung Bioepis(CEO/President Han-Seung Ko) agreed on the patent conflict about SB5(generic name: adalimumab, biosimilar referencing Humira), a biosimilar for the treatment of autoimmune disease(Anti-TNF-α).

Samsung Bioepis announced the company signed a license agreement with AbbVie, the original company of SB5, and agreed on the patent conflict. Under the agreement, Samsung Bioepis will be a...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.